The Department of Health must urgently clarify how the move to ‘value-based pricing’ next year will affect the availability of drugs for patients, say MPs. A report from the House of Commons Health ...

The DSU has been working to support NICE with the implementation of Value Based Pricing (now Value Based Assessment) in 2013-14. We have produced reports which consider the issues associated with ...

NICE has called on the Government to scale back its plans to overhaul the drug pricing and evaluation system in order to avoid a postcode lottery in access to new drugs. In its response to the ...

James Jay Barber, President and CEO, opened by noting his transition into the role and outlined a focused strategy: "what I believe this business needs now is a sharp focus on commercial processes, ...

Initiating Vestis Corporation with a Buy rating and $9.10 fair value, driven by the new CEO's value-based pricing and cost optimization strategy. Despite recent revenue declines and customer losses, I ...